



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts

Public declaration of interests

I, **Aristotelis Bamias**

Organisation/Company: NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS

Country: Greece

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
10/2015-12/2018	Astra Zeneca	Olaparib	BRCA mutant ovarian cancer
12/2016-06/2020	BMS	Nivolumab	Renal cancer, Urothelial cancer
03/2014-11/2020	MSD	Pembrolizumab	Urothelial cancer
04/2016-04/2018	Pfizer	Treatment of renal cancer- Axitinib	
11/2017-11/2020	IPSEN	Cabozantinib	Renal cancer

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
05/2016-(current)	ROCHE	Atezolizumab	Urothelial cancer
11/2016-06/2019	Novartis	Pazopanib	Renal cancer
09/2020-(current)	GSK	Zevelo	Ovarian cancer

Classified as public by the European Medicines Agency

## 2.4 Financial interests

No interest declared

## 2.5 Principal investigator

No interest declared

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
09/2016-(current)	Roche	Atezolizumab	Urothelial cancer 1st line
10/2016-(current)	BMS	Nivolumab	Urothelial cancer adjuvant
04/2016-(current)	Pfizer	Avelumab	Ovarian cancer
12/2016-(current)	Pfizer	Avelumab	Urothelial cancer maintenace
04/2015-(current)	Roche	Atezolizumab	Urothelial cancer-2nd line
02/2016-(current)	Roche	Bevacizumab	Cervical cancer
04/2016-10/2019	Astra Zeneca	Durvalumab	Urothelial cancer-1st line
05/2016-10/2019	Roche	Atezolizumab	Urothelial cancer-adjuvant
06/2016-09/2019	Sanofi	Cabazitaxel	Prostate cancer
09/2017-(current)	EISAI	Lenvatinib	Renal cancer
03/2018-(current)	Roche	Atezolizumab	Ovarian cancer 1st-line
03/2018-(current)	BMS	Nivolumab	Urothelial cancer 1st-line
02/2018-(current)	Roche	Atezolizumab	Prostate Cancer
05/2018-(current)	Janssen-Cilag	Erdafitinib	Urothelial cancer relapsed

## 2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Janssen-Cilag	Prostate cancer

## 2.8 Close family member interest

No interest declared

## 2.9 Repurposing of a medicinal product

No interest declared

## 2.10 Any other interests or facts

Member of the Genitourinary Cancer Faculty of the European Society of Medical Oncology (ESMO) since 2012

Academic trials during the last 3 years

1. EFFICACY AND SAFETY OF BEVACIZUMAB/TEMSIROLIMUS COMBINATION AFTER FIRST-LINE anti-VEGF THERAPY IN ADVANCED RENAL CELL CARCINOMA

EudraCT: 2010-020664-38

Sponsor: Hellenic Co-operative Oncology Group (HeCOG)

Funding by: Pfizer

2. A Retrospective Analysis of the Effectiveness of Everolimus as Second-line Treatment in Metastatic RCC after Failure/Intolerance of Pazopanib. The 'RESCUE' Study

Sponsor: Hellenic Genito-Urinary Cancer Group (HGUCG)

Funding by: Novartis

3. Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece -the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).

Sponsor: Hellenic Genito-Urinary Cancer Group (HGUCG)

Funding by: Novartis

4. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers TRINOVA-3

Sponsor: Belgian Gynaecological Oncology Group (BGOG)

Funding by: Amgen

5. Intravesical administration of Durvalumab (MEDI4736) to patients with high-risk, non-muscle-invasive bladder cancer (NMIBC). A phase II study with correlative biomarker studies

Sponsor: Hellenic Genito-Urinary Cancer Group (HGUCG)

Funding by: Astra Zeneca

6. OUTCOMES FROM TREATMENT OF METASTATIC RENAL-CELL CARCINOMA FOLLOWING FAILURE OF FIRST-LINE ANTI-VEGF/VEGFR THERAPY: REAL-LIFE EVIDENCE ON THE CHANGE OF THE TREATMENT PARADIGM-OVERCOME STUDY

Sponsor: Hellenic Genito-Urinary Cancer Group (HGUCG)

Funding by: Pfizer

7. Nivolumab plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC) not undergoing cystectomy: a phase II, randomized study.

Sponsor: Hellenic Genito-Urinary Cancer Group (HGUCG)

Funding by: BMS

## 2.11 CAT member or alternate

No interest declared

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	ARISTOTELIS BAMIAS
Date:	2020-12-29

*For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template*